Deutsche Bank Aktiengesellschaft Reaffirms “Hold” Rating for AstraZeneca (LON:AZN)

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday, MarketBeat Ratings reports. The firm currently has a £105 ($129.69) price target on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Berenberg Bank reiterated a buy rating on shares of AstraZeneca in a research note on Wednesday, March 13th. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a research note on Monday, February 12th. UBS Group cut their target price on AstraZeneca from £107 ($132.16) to GBX 9,900 ($122.28) and set a sell rating on the stock in a research note on Monday, February 12th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research note on Thursday, April 4th. Finally, Shore Capital reissued a buy rating on shares of AstraZeneca in a report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca has a consensus rating of Moderate Buy and an average target price of £116.86 ($144.34).

AstraZeneca Stock Performance

Shares of AZN opened at £119.88 ($148.07) on Tuesday. The business’s fifty day simple moving average is £105.78 and its two-hundred day simple moving average is £104.52. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. AstraZeneca has a 12 month low of GBX 9,461 ($116.86) and a 12 month high of £121.86 ($150.52). The company has a market cap of £185.81 billion, a price-to-earnings ratio of 3,956.44, a P/E/G ratio of 0.89 and a beta of 0.19.

AstraZeneca Increases Dividend

The business also recently announced a dividend, which was paid on Monday, March 25th. Investors of record on Thursday, February 22nd were issued a GBX 156 ($1.93) dividend. This is a boost from AstraZeneca’s previous dividend of $71.80. This represents a yield of 1.49%. The ex-dividend date of this dividend was Thursday, February 22nd. AstraZeneca’s dividend payout ratio (DPR) is currently 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.